title: The ability of cultured Langerhans cells to process and present protein antigens is MHC-dependent.
abstract: There is controversy regarding the ability of short term (2 to 3 days) cultured epidermal Langerhans cells (cLC) to process and present intact protein Ag to primed T cells. Some studies have shown that cLC are potent APC for both haptens and intact protein Ag, whereas in others cLC have been unable to process and present intact protein Ag. In an attempt to resolve this controversy, we tested the ability of Langerhans cells from several strains of mice to process and present intact protein Ag to T cell clones and T cell hybridomas. We found that both cLC and freshly prepared Langerhans cells from various Iak mice, including BALB.k mice, process and present intact protein antigens (i.e., hen egg lysozyme, cytochrome c, and OVA) to T cells. These functions are retained in cLC cultured for 7 days. In contrast, cLC from Iad mice do not process intact protein Ag, such as hen egg lysozyme and myoglobin, although they can present relevant peptides to specific T cells and are potent stimulators of allogeneic responses. Furthermore, cLC from (Iak x Iad)F1 mice process and present intact protein Ag to Iak-restricted T cells, but not to Iad-restricted T cells. Although cLC that processed and presented intact protein Ag to T cells exhibited enhanced class II MHC expression, they were, on a per cell basis, somewhat less efficient than were fresh Langerhans cells. Finally, we found that if Iad Langerhans cells are pulsed with intact protein Ag and then cultured for 3 days, they are then fully capable of inducing Ag- and MHC-specific T cell proliferation.
authors.affiliation: Dermatology Branch, NCI/NIH, Bethesda, MD 20892.
authors.forename: S
authors.initials: S
authors.lastname: Aiba
authors.forename: S I
authors.initials: SI
authors.lastname: Katz
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D002455:Cell Division; D002478:Cells, Cultured; D002738:Chloroquine / Q000494:pharmacology; D003574:Cytochrome c Group / Q000494:pharmacology; D004306:Dose-Response Relationship, Immunologic; D005434:Flow Cytometry; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D006825:Hybridomas / Q000276:immunology; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis; D007515:Islets of Langerhans / Q000187:drug effects / Q000276:immunology*; D008285:Major Histocompatibility Complex; D051379:Mice; D008815:Mice, Inbred Strains; D009113:Muramidase / Q000494:pharmacology; D009211:Myoglobin / Q000494:pharmacology; D010047:Ovalbumin / Q000494:pharmacology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D013997:Time Factors
chemical_list: D003574:Cytochrome c Group; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D009211:Myoglobin; D002738:Chloroquine; D010047:Ovalbumin; D009113:Muramidase